How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors
2018/06/06 by Imran Aziz, Hans Törnblom, Olafur S Palsson +4 · 27 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Gastrointestinal motility and disorders #Inflammatory Bowel Disease #Diverticular Disease and Complications
paper · doi:10.1038/s41395-018-0074-z
Abstract
OBJECTIVES: The diagnostic criteria for irritable bowel syndrome (IBS) have recently been updated from Rome III to Rome IV. Whereas in Rome III a diagnosis of IBS entailed chronic abdominal pain or discomfort at least 3 days per month, in Rome IV the term discomfort has been removed and the frequency of abdominal pain increased to at least 1 day per week. We examined how this change in IBS criteria impacts on clinical characteristics and pathophysiological factors. METHODS: A total of 542 Swedish subjects with Rome III IBS completed a baseline questionnaire enquiring for the number of abdominal pain days in the last 10 days; this was subsequently used as a surrogate marker to identify Rome IV IBS, in that (a) those with 0 or 1 day of pain were classed as Rome IV-negative, and (b) those with ≥2 days of pain were classed as Rome IV-positive. Comparisons were made between Rome IV-positive and -negative IBS groups for demographics, IBS subtype, gastrointestinal and psychological symptoms, somatisation, fatigue, disease-specific quality of life, rectal sensitivity, and oro-anal transit time. RESULTS: Overall, 85% of Rome III IBS patients fulfilled the Rome IV criteria for IBS, but 15% did not. Rome IV-positive subjects were significantly more likely to be female, have poorer quality of life, greater pain severity, bloating, somatisation, fatigue, and rectal sensitivity than Rome IV-negative subjects. There were no differences in severity of anxiety or depression, IBS subtypes, bowel habit dissatisfaction, or oro-anal transit time. Finally, increasing number of pain days correlated positively with symptoms and visceral hypersensitivity. CONCLUSIONS: Most Rome III-positive IBS patients seeking healthcare fulfil the Rome IV IBS criteria. They constitute a more severe group than those who lose their IBS diagnosis.
Citations
Cited by
- Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options
- British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
- Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human. [europepmc]
- Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. [europepmc]
- Prevalence and impact of self-reported irritable bowel symptoms in the general population. [europepmc]
- The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome. [europepmc]
- Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome. [europepmc]
- The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study. [europepmc]
- Irritable Bowel Syndrome: Straightening the road from the Rome criteria. [europepmc]
- High prevalence of primary bile acid diarrhoea in patients with functional diarrhoea and irritable bowel syndrome-diarrhoea, based on Rome III and Rome IV criteria. [europepmc]
- Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial. [europepmc]
- Prevalence and trigger factors of functional gastrointestinal disorders among male civil pilots in China. [europepmc]
- Rome III, Rome IV, and Potential Asia Symptom Criteria for Functional Dyspepsia Do Not Reliably Distinguish Functional From Organic Disease. [europepmc]
- Sex-Bias in Irritable Bowel Syndrome: Linking Steroids to the Gut-Brain Axis. [europepmc]
- Irritable Bowel Syndrome: Prevalence and Risk Factors in Jazan Region, Saudi Arabia. [europepmc]
- The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. [europepmc]
- Spinal cord astrocyte P2X7Rs mediate the inhibitory effect of electroacupuncture on visceral hypersensitivity of rat with irritable bowel syndrome. [europepmc]
- Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. [europepmc]
- Extraintestinal manifestations in irritable bowel syndrome: A systematic review. [europepmc]
- Factors related to irritable bowel syndrome and differences among subtypes: A cross-sectional study in the UK Biobank. [europepmc]
- Two Gold Kiwifruit Daily for Effective Treatment of Constipation in Adults-A Randomized Clinical Trial. [europepmc]
- Gender Influences Gut Microbiota among Patients with Irritable Bowel Syndrome. [europepmc]
- The Long-Term Effects of a Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Irritable Bowel Syndrome Management. [europepmc]
- Contribution of sex and gender roles to the incidence of post-infectious irritable bowel syndrome in a prospective study. [europepmc]
- Site and duration of abdominal pain discriminate symptomatic uncomplicated diverticular disease from previous diverticulitis patients. [europepmc]
- Epidemiology of Disorders of the Gut-Brain Interaction: An Appraisal of the Rome IV Criteria and Beyond. [europepmc]
- Impact of Enteric Nervous Cells on Irritable Bowel Syndrome: Potential Treatment Options. [europepmc]
Related